Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to shrink liver tumors in First-Line patients

NCT ID NCT07291076

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 6 times

Summary

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pumitamig (a drug) and ipilimumab (an immunotherapy drug)
What this could lead to
If successful, this could provide a new treatment option for people with advanced liver cancer who have not had prior therapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drugs may not work or could cause serious side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 198 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC). * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participants must have no prior systemic therapy for advanced/ unresectable HCC. * Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria * Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence. * Participants must not have an organ transplant or autoimmune disease. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    66 sites in 14 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea

  • Azienda Ospedaliero Universitaria Pisana

    RECRUITING

    Pisa, Tuscany, 56126, Italy

  • Bradfordhill

    RECRUITING

    Santiago, Santiago Metropolitan, 8420383, Chile

  • CHU Bordeaux Haut-Leveque

    RECRUITING

    Pessac, Aquitaine, 33600, France

  • Cancer Research UK - The Beatson Institute for Cancer Research (Cancer Research UK Beatson Laboratories)

    RECRUITING

    Glasgow, South Western Scotland, G611BD, United Kingdom

  • Centre Hospitalier Universitaire de Grenoble

    RECRUITING

    La Tronche, Auvergne-Rhône-Alpes, 38700, France

  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord

    RECRUITING

    Saint Priest En Jarez, Pays de la Loire Region, 42270, France

  • Cha Bundang Medical Center, Cha University

    RECRUITING

    Seongnam-si, Kyǒnggi-do, 13496, South Korea

  • China Medical University Hospital

    RECRUITING

    Taichung, 404332, Taiwan

  • Hammersmith Hospital

    RECRUITING

    London, London, City of, W12 0HS, United Kingdom

  • Hospital General Universitario Gregorio Marañon

    RECRUITING

    Madrid, 28007, Spain

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

    RECRUITING

    Meldola, Emilia-Romagna, 47014, Italy

  • John Theurer Cancer Center at Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601-2191, United States

  • Local Institution - 0001

    NOT_YET_RECRUITING

    Montpellier, Languedoc-Roussillon, 34295, France

  • Local Institution - 0003

    NOT_YET_RECRUITING

    Bobigny, 93000, France

  • Local Institution - 0008

    NOT_YET_RECRUITING

    Kashiwa, 277-8577, Japan

  • Local Institution - 0009

    NOT_YET_RECRUITING

    Singapore, 119074, Singapore

  • Local Institution - 0014

    NOT_YET_RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Local Institution - 0015

    NOT_YET_RECRUITING

    Barcelona, 08036, Spain

  • Local Institution - 0016

    NOT_YET_RECRUITING

    Pisa, 56126, Italy

  • Local Institution - 0017

    NOT_YET_RECRUITING

    Osakasayama-shi, Osaka, 5898511, Japan

  • Local Institution - 0020

    NOT_YET_RECRUITING

    Gdansk, 80-952, Poland

  • Local Institution - 0021

    NOT_YET_RECRUITING

    Wroclaw, Lower Silesian Voivodeship, 53-439, Poland

  • Local Institution - 0026

    NOT_YET_RECRUITING

    Mainz, 55101, Germany

  • Local Institution - 0031

    NOT_YET_RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Local Institution - 0033

    NOT_YET_RECRUITING

    Westmead, New South Wales, 2145, Australia

  • Local Institution - 0053

    NOT_YET_RECRUITING

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Local Institution - 0070

    NOT_YET_RECRUITING

    Los Angeles, California, 90064, United States

  • Local Institution - 0075

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510515, China

  • Local Institution - 0078

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Local Institution - 0083

    NOT_YET_RECRUITING

    Seattle, Washington, 98109-1024, United States

  • Local Institution - 0086

    NOT_YET_RECRUITING

    Xi'an, Shaanxi, 710126, China

  • Local Institution - 0089

    NOT_YET_RECRUITING

    Milan, 20132, Italy

  • Local Institution - 0095

    NOT_YET_RECRUITING

    Madrid, 28050, Spain

  • Local Institution - 0100

    NOT_YET_RECRUITING

    Mineola, New York, 11501, United States

  • Local Institution - 0105

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, 02-106, Poland

  • Local Institution - 0107

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

  • Local Institution - 0114

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Local Institution - 0115

    WITHDRAWN

    Xi'an, Shaanxi, 710038, China

  • Local Institution - 0116

    NOT_YET_RECRUITING

    Fuzhou, Fujian, 350028, China

  • Local Institution - 0118

    NOT_YET_RECRUITING

    Jinan, Shandong, 250117, China

  • Local Institution - 0119

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Local Institution - 0122

    NOT_YET_RECRUITING

    Hefei, Anhui, 230001, China

  • Local Institution - 0123

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, 330006, China

  • Local Institution - 0125

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, 400016, China

  • Local Institution - 0126

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310022, China

  • Local Institution - 0128

    NOT_YET_RECRUITING

    Nanyang, Henan, 473000, China

  • Local Institution - 0129

    NOT_YET_RECRUITING

    Nanning, Guangxi, 530200, China

  • Local Institution - 0130

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, 150001, China

  • Local Institution - 0134

    NOT_YET_RECRUITING

    Detroit, Michigan, 48202, United States

  • Local Institution - 0137

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

  • Local Institution - 0138

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610072, China

  • National Cancer Centre Singapore

    RECRUITING

    Singapore, 168583, Singapore

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, 704, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10002, Taiwan

  • Pontifica Universidad Catolica De Chile

    RECRUITING

    Santiago Region Metropolitana, Santiago Metropolitan, 8330034, Chile

  • Providence Portland Medical Center

    RECRUITING

    Portland, Oregon, 97213, United States

  • Providence St. Vincent Medical Center

    RECRUITING

    Portland, Oregon, 97225, United States

  • Royal Prince Alfred Hospital

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Samsung Medical Center

    RECRUITING

    Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea

  • Sunshine Coast University Hospital

    RECRUITING

    Birtinya, Queensland, 4575, Australia

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The Royal Melbourne Hospital

    RECRUITING

    Parkville, Victoria, 3052, Australia

  • Universitaetsklinikum Frankfurt

    RECRUITING

    Frankfurt, D-60590, Germany

  • Universitatsklinikum Schleswig-Holstein

    RECRUITING

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.